Format

Send to

Choose Destination
Trends Biotechnol. 2019 Jun;37(6):578-591. doi: 10.1016/j.tibtech.2018.11.009. Epub 2018 Dec 18.

Targeting the Post-translational Proteome with Intrabodies.

Author information

1
Bio@SNS Laboratory, Scuola Normale Superiore, Piazza dei Cavalieri, 7 - 56126 Pisa, Italy. Electronic address: antonino.cattaneo@sns.it.
2
Bio@SNS Laboratory, Scuola Normale Superiore, Piazza dei Cavalieri, 7 - 56126 Pisa, Italy; Current address: Institute for Research in Biomedicine, Università della Svizzera italiana (USI), Via Vincenzo Vela 6, CH-6500 Bellinzona, Switzerland.

Abstract

The complexity of the proteome exceeds that of the genome. Post-translational modifications (PTMs) and conformational changes of proteins trigger new molecular interactions whose systematic elucidation is hampered by the lack of specific tools. PTMs are particularly relevant for epigenetic regulation of gene expression; a field of translational interest. However, state-of-the-art inhibitors used in epigenetic studies and therapies target modifier enzymes such as acetylases and deacetylases, rather than a single PTM protein per se. The systematic development of anti-PTM intrabodies, which allow targeting of intracellular proteins in the context of living cells, will help reaching a new level of precision and specificity in the description of epigenetics, paving the way to new therapeutic opportunities.

KEYWORDS:

PISA; intrabody; post-translational modifications; proteome; recombinant antibody

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center